Search Bar & Filters
Found 31 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.
Actively Recruiting
Researchers are evaluating the efficacy and safety of FT819, a treatment made of allogeneic T cells expressing a CD19-targeted CAR, for people with moderate-to-severe systemic lupus erythematosus SLE who have lupus nephritis LN that has not responded to at least two prior immunosuppressive treatments. This phase 2, open-label, single-arm trial focuses on participants aged 12 to 70 with biopsy-proven Class III or IV LN and active disease. The study aims to measure how many participants achieve complete renal response at 26 weeks. Participants will first undergo a screening period lasting up to 28 days. After screening, they will receive bendamustine treatment followed by a single intravenous infusion of FT819. The study will include efficacy, safety, and exploratory assessments at scheduled timepoints through 24 months of post-treatment follow-up. After this, participants will be monitored for safety and survival for up to 15 years in a long-term follow-up phase. Throughout the study, researchers will assess lupus nephritis activity using standard measures, including complete and partial renal responses, and clinician-reported outcomes such as SLEDAI-2K, BILAG, and PGA scores. Safety and disease activity evaluations will take place at predefined visits. The total duration of participation includes multiple assessments during the first two years and extended long-term monitoring up to 15 years to observe ongoing effects and survival.
Actively Recruiting
Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.
Actively Recruiting
Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.
Actively Recruiting
Researchers are evaluating the effects of nivolumab combined with blinatumomab compared to blinatumomab alone in patients with first relapse B-cell acute lymphoblastic leukemia B-ALL, including those with Down syndrome. This phase II trial aims to assess event-free survival and safety in children and young adults aged 1 to under 31 years. The study also explores remission rates and adverse events related to these treatments. Participants receive different combinations of blinatumomab, nivolumab, dexamethasone, methotrexate, and other chemotherapy drugs depending on their assigned group or arm. Treatment cycles generally last 36 to 37 days and may repeat up to two cycles if no disease progression or unacceptable toxicity occurs. Additional therapies like radiation and intrathecal chemotherapy are given based on disease characteristics. Down syndrome patients have a specific treatment arm with tailored medication schedules. Throughout the study, participants undergo lumbar punctures, bone marrow biopsies and aspirations, and collection of blood, urine, and cerebrospinal fluid for monitoring. Follow-up visits occur every three months for one year after treatment completion to assess outcomes such as minimal residual disease negative remission and event-free survival. Safety and tolerability are closely monitored during therapy and follow-up.
Actively Recruiting
Researchers are studying the effects of anifrolumab, given as a 120 mg subcutaneous injection once weekly, for patients with systemic lupus erythematosus SLE who have not used immunosuppressants or biologic therapies before. The study aims to understand clinical outcomes like remission rates and the ability to taper off glucocorticoids GCs safely in patients not meeting low disease activity status at enrollment. Participants will receive anifrolumab injections weekly for 52 weeks, alongside their usual antimalarial treatment, with or without glucocorticoids. The study includes a 35-day screening period before treatment starts. Glucocorticoid doses may be increased during the first 4 weeks if needed, then tapered gradually between weeks 5 and 40 following a specific protocol. Those achieving remission can attempt complete withdrawal of glucocorticoids after tapering. After week 41, glucocorticoid doses will remain stable. Safety follow-up occurs 12 weeks after the last dose for participants who stop treatment after week 52. Participants will undergo regular assessments throughout the study to evaluate disease activity, remission status, glucocorticoid use, and quality of life. Researchers will monitor various outcomes, including time spent in remission, flare occurrences, skin and joint symptoms, and adverse events. The total participation time is approximately 69 weeks, including screening, treatment, and safety follow-up, with detailed tracking of glucocorticoid use and disease status at multiple time points.
Actively Recruiting
Researchers are evaluating how well the 20-valent pneumococcal conjugate vaccine 20vPnC works against pneumonia caused by seven new types of the Streptococcus pneumoniae bacteria. This study focuses on adults aged 65 years and older who are hospitalized with pneumonia confirmed by chest imaging. The study aims to compare the presence of pneumonia caused by these specific bacteria types in people vaccinated with 20vPnC versus those with pneumonia caused by other bacteria or strains. This observational study involves adults 65 years and older hospitalized with radiologically-confirmed community-acquired pneumonia RADCAP. Participants will provide a urine sample for testing pneumococcal bacteria using BinaxNOW and specific urinary antigen detection assays UAD-1 and UAD-2. Cases are identified by detection of the seven additional bacteria types in 20vPnC beyond the previous 13-valent vaccine, while controls include other pneumonia cases without these serotypes. No treatment is given as part of the study. Participants will be involved for about 1 to 2 days for urine sample collection and providing medical history. Researchers will collect detailed information on illness and hospital stay up to 30 days through medical record review. The main outcome measured is the effectiveness of 20vPnC against pneumonia caused by the seven additional bacterial types over approximately 55 months. Other clinical features and pneumonia types will also be reviewed during this period.
Actively Recruiting
Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.
Actively Recruiting
Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.
Actively Recruiting
Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.
1-10 of 31
1